Biotech Values

[DewDiligence]

The AMRN proxy fight is getting nasty:

https://www.businesswire.com/news/home/20230216005822/en

Sarissa Capital is outraged but not surprised by Amarin’s repeated false statements intended to mislead shareholders and switch votes away from Sarissa.

Amarin has made these false statements throughout this proxy contest, including in its evaluation of the company’s progress and its own performance, in its characterizations of the board’s interactions with Sarissa, and, most recently, in the failure of its registrar to be properly instructed. Clearly, Amarin is willing to say anything to keep Sarissa, its largest shareholder, off the board.

Emphasis in source document.